- Home
- IDN vs ZNTL Comparison
IDN vs ZNTL Comparison
Compare IDN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDN | ZNTL |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6M | 118.3M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IDN | ZNTL |
|---|---|---|
| Price | $6.45 | $1.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $6.50 | $5.87 |
| AVG Volume (30 Days) | ★ 923.4K | 554.4K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $21,968,000.00 | ★ $26,865,000.00 |
| Revenue This Year | $9.73 | N/A |
| Revenue Next Year | $11.75 | N/A |
| P/E Ratio | $665.36 | ★ N/A |
| Revenue Growth | ★ 14.20 | N/A |
| 52 Week Low | $2.17 | $1.01 |
| 52 Week High | $7.48 | $4.00 |
Technical Indicators
Market Signals| Indicator | IDN | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 49.07 |
| Support Level | $5.91 | $1.31 |
| Resistance Level | $6.56 | $1.39 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 46.12 | 66.67 |
Price Performance
Historical ComparisonAbout IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.